Abattis Bioceuticals Corp.

OTCPK:ATTB.F Stock Report

Market Cap: US$476.0

Abattis Bioceuticals Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenure6.5yrs
Board average tenure6yrs

Recent management updates

No updates

Recent updates

No updates


CEO

Abattis Bioceuticals has no CEO, or we have no data on them.


Leadership Team

NamePositionTenureCompensationOwnership
Francesco Paolini
CFO & Director5.8yrsno datano data
Patrick Mitchell
COO & Director6.2yrsno datano data
Shawn Balaghi
Head of Corporate Development6.7yrsno datano data
Jim Carter
Head of Mergers and Acquisitions Advisory6.7yrsno datano data
Christopher Cherry
Corporate Comptroller8.3yrsno datano data
Nicole Breitinger
Corporate Secretary6.3yrsno datano data

6.5yrs

Average Tenure

Experienced Management: ATTB.F's management team is seasoned and experienced (6.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Francesco Paolini
CFO & Director5.8yrsno datano data
Patrick Mitchell
COO & Director5.3yrsno datano data
Brazos Arthur Minshew
Head of the Medical Advisory Board6.7yrsno datano data
Cedric Wilson
Director6.3yrsno datano data

6.0yrs

Average Tenure

Experienced Board: ATTB.F's board of directors are considered experienced (6 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/21 05:46
End of Day Share Price 2025/01/17 00:00
Earnings2019/09/30
Annual Earnings2019/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Abattis Bioceuticals Corp. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Siddharth RajeevFundamental Research Corp.